Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
2.900
-0.060 (-2.03%)
At close: May 30, 2025, 4:00 PM
3.040
+0.140 (4.83%)
After-hours: May 30, 2025, 4:02 PM EDT

Kalaris Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
-75.96-69.17-14.7-15.49
Other Amortization
37.4138.020.891.99
Asset Writedown & Restructuring Costs
---0.16
Stock-Based Compensation
1.240.90.150.27
Other Operating Activities
11.4211.710.62-0.11
Change in Accounts Payable
1.14-1.03-0.41.83
Change in Other Net Operating Assets
1.16-1.1-0.691.57
Operating Cash Flow
-23.59-20.67-14.13-9.78
Short-Term Debt Issued
-19.97--
Long-Term Debt Issued
--64.3
Total Debt Issued
22.4719.9764.3
Net Debt Issued (Repaid)
22.4719.9764.3
Issuance of Common Stock
00-0.01
Other Financing Activities
97.35-2.42--
Financing Cash Flow
119.8319.1414.2412.78
Net Cash Flow
96.24-1.530.113
Levered Free Cash Flow
--18.82-9.43-
Unlevered Free Cash Flow
--31.39-9.34-
Change in Net Working Capital
--0.051.07-
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.